Valuation: Gilead Sciences, Inc.

Market Cap 208B 189B 175B 158B 298B 19,575B 309B 2,104B 834B 10,505B 782B 766B 33,274B P/E 2026 *
-39.5x
P/E 2027 * 20.2x
Enterprise Value 230B 209B 193B 174B 328B 21,551B 340B 2,317B 918B 11,565B 861B 843B 36,634B EV / Sales 2026 *
7.31x
EV / Sales 2027 * 6.55x
Free-Float
99.88%
Yield 2026 *
1.96%
Yield 2027 * 2.01%
1 day-0.30%
1 week+0.41%
Current month-1.82%
1 month+6.49%
3 months+21.12%
6 months+29.33%
Current year+36.53%
1 week 166.75
Extreme 166.75
171.8
1 month 151.71
Extreme 151.71
176.58
Current year 116.88
Extreme 116.88
176.58
1 year 116.88
Extreme 116.88
176.58
3 years 62.07
Extreme 62.07
176.58
5 years 57.16
Extreme 57.165
176.58
10 years 56.56
Extreme 56.56
176.58
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
11/2/26 A Sell

Chief Executive Officer

-15,000 0.0012%
10/15/26 A Sell

Executive/Senior Manager

-3,000 0.0002%
10/15/26 A Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%+0.41%+34.04%+123.32% 208B
-0.82%+5.74%+39.64%+143.26% 1,286B
-1.12%+2.29%+44.21%+89.89% 688B
-0.16%+1.11%+26.76%+114.06% 521B
+1.14%+4.87%+43.06%+71.97% 386B
-2.23%-1.55%+55.47%+42.54% 364B
+1.27%+2.01%+30.01%+62.35% 302B
+0.37%+0.75%+3.71%+39.09% 287B
-0.72%+0.41%+37.29%+69.33% 252B
+2.44%+5.86%-8.29%-57.68% 181B
Average +0.26%+2.20%+30.59%+69.81% 448B
Weighted average by Cap. -0.01%+3.26%+35.14%+91.95%

Financials

2026 *2027 *
Net sales 31.38B 28.51B 26.34B 23.79B 44.91B 2,947B 46.48B 317B 126B 1,581B 118B 115B 5,009B 33.6B 30.53B 28.21B 25.48B 48.08B 3,155B 49.77B 339B 134B 1,693B 126B 123B 5,363B
Net income -5.29B -4.81B -4.44B -4.01B -7.57B -497B -7.84B -53.42B -21.17B -267B -19.86B -19.44B -845B 10.7B 9.72B 8.98B 8.11B 15.31B 1,004B 15.84B 108B 42.78B 539B 40.14B 39.29B 1,707B
Net Debt 21.05B 19.12B 17.67B 15.96B 30.12B 1,976B 31.17B 212B 84.18B 1,061B 78.98B 77.3B 3,359B 11.61B 10.55B 9.75B 8.8B 16.61B 1,090B 17.2B 117B 46.44B 585B 43.57B 42.65B 1,853B
Projected Income Statement - Annual - Gilead Sciences, Inc.
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
17/11/26 $167.58 -0.30% 4,582,784
13/11/26 $168.08 +0.08% 3,637,695
12/11/26 $167.95 -1.05% 4,233,733
11/11/26 $169.73 -0.67% 4,883,537
10/11/26 $170.87 +0.92% 4,830,594
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Gilead Sciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
168.08USD
Average target price
175.92USD
Spread / Average Target
+4.67%
  1. Stock Market
  2. Stocks
  3. GILD Stock